BioPharma Resources

Drug Trial Radar · NCT04954859

Long-term Follow-up Study to Evaluate Durability of Treatment Response in Previous Bepirovirsen Study Participants (B-Sure)

A Prospective, Multi-Centre Study (B-Sure) to Evaluate Long-Term Durability of Treatment Response in Chronic Hepatitis B Participants With and Without Nucleos(t)Ide Therapy Who Have Participated in a Previous Bepirovirsen Treatment Study

Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

366

Actual

Start

Dec 14, 2021

Primary completion

Jan 24, 2029

Study completion Jan 24, 2029

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Jul 8, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a global multi-center, long-term follow-up study to assess durability of efficacy, as measured by maintenance of treatment response from the parent study, in participants who participated in a previous bepirovirsen study and achieved a complete or partial response. Eligible participants will be enrolled in this study after completing the end of study (EoS) visit in the respective parent bepirovirsen studies (studies B-Clear \[209668: NCT04449029\], B-Together \[209348: NCT04676724\], B-Fine \[212602: NCT04544956\], B-Well 1 \[202009: NCT05630807\], B-Well 2 \[219288: NCT05630820\], and TH HBV ASO-001 \[217023: NCT05276297\]). Participants will be categorized as Not-on-NA, NA-cessated, or On-NA based on their nucleos(t)ide analogue (NA) status in the parent study. No further treatment with bepirovirsen will be administered in this study.

Conditions

  • Hepatitis B

Interventions

  • BepirovirsenDrug

    No study drug will be administered in this study. Eligible participants who received prior treatment with bepirovirsen in the parent studies will be included.

  • PlaceboDrug

    No study drug will be administered in this study. Eligible participants who received prior treatment with placebo in the parent studies (209668, 202009, and 219288) will be included to maintain the blind in the still ongoing parent studies.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Not-on-NA participants without loss of parent study primary outcome (PSPO)Time frame: From primary endpoint assessment in the parent study up to Month 57
  2. Percentage of On-NA participants rolling over from studies 209668 and 209348 without loss of functional cure (FC) after NA-cessation in study 206882Time frame: From Month 3 up to Month 57
  3. Percentage of On-NA participants rolling over from study 217023 without loss of FC after NA-cessation in study 206882Time frame: From Month 3 up to Month 33
  4. Percentage of NA-cessated participants rolling over from studies 202009 and 219288 without loss of FC after NA-cessation in the parent studyTime frame: From primary endpoint assessment in the parent study up to Month 33

Locations

161 sites in 29 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Sacramento, California

  • GSK Investigational Site

    San Jose, California

  • GSK Investigational Site

    Colorado Springs, Colorado

  • GSK Investigational Site

    Boston, Massachusetts

  • GSK Investigational Site

    Detroit, Michigan

  • GSK Investigational Site

    Buenos Aires, Argentina

  • GSK Investigational Site

    Buenos Aires, Argentina

  • GSK Investigational Site

    Rosario, Argentina

  • GSK Investigational Site

    Santa Fe, Argentina

  • GSK Investigational Site

    La Plata, Buenos Aires, Argentina

  • GSK Investigational Site

    Herston, Queensland, Australia

  • GSK Investigational Site

    Fitzroy, Victoria, Australia

  • GSK Investigational Site

    Campinas, Brazil

  • GSK Investigational Site

    Curitiba, Brazil

  • GSK Investigational Site

    Manaus, Brazil

  • GSK Investigational Site

    São Paulo, Brazil

  • GSK Investigational Site

    Vila Mariana, Brazil

  • GSK Investigational Site

    Aracaju, Sergipe, Brazil

  • GSK Investigational Site

    Plovdiv, Bulgaria

  • GSK Investigational Site

    Sliven, Bulgaria

  • GSK Investigational Site

    Sofia, Bulgaria

  • GSK Investigational Site

    Sofia, Bulgaria

  • GSK Investigational Site

    Sofia, Bulgaria

  • GSK Investigational Site

    Varna, Bulgaria

  • GSK Investigational Site

    Calgary, Alberta, Canada

  • GSK Investigational Site

    Victoria, British Columbia, Canada

  • GSK Investigational Site

    Toronto, Ontario, Canada

  • GSK Investigational Site

    Montreal, Quebec, Canada

  • GSK Investigational Site

    Montreal, Quebec, Canada

  • GSK Investigational Site

    Québec, Quebec, Canada

  • GSK Investigational Site

    Beijing, China

  • GSK Investigational Site

    Beijing, China

  • GSK Investigational Site

    Beijing, China

  • GSK Investigational Site

    Chengdu, China

  • GSK Investigational Site

    Chengdu, China

  • GSK Investigational Site

    Chongqing, China

  • GSK Investigational Site

    Fuzhou, China

  • GSK Investigational Site

    Guangzhou, China

  • GSK Investigational Site

    Guangzhou, China

  • GSK Investigational Site

    Guangzhou, China

Showing 40 of 161 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.